TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Short Interest Update

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) saw a large increase in short interest in August. As of August 14th, there was short interest totaling 20,535 shares, an increase of 70.4% from the July 30th total of 12,050 shares. Based on an average trading volume of 3,313 shares, the days-to-cover ratio is currently 6.2 days.

TriSalus Life Sciences Price Performance

Shares of NASDAQ TLSIW traded down $0.01 during mid-day trading on Monday, reaching $0.89. The company had a trading volume of 384 shares, compared to its average volume of 5,208. The stock has a fifty day moving average of $0.85 and a two-hundred day moving average of $0.96. TriSalus Life Sciences has a 12-month low of $0.44 and a 12-month high of $2.19.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Cerity Partners LLC purchased a new stake in TriSalus Life Sciences in the 4th quarter worth approximately $1,374,000. Citadel Advisors LLC grew its holdings in shares of TriSalus Life Sciences by 439.0% during the 3rd quarter. Citadel Advisors LLC now owns 126,876 shares of the company’s stock valued at $199,000 after acquiring an additional 103,336 shares in the last quarter. Fort Baker Capital Management LP acquired a new position in shares of TriSalus Life Sciences in the fourth quarter worth $44,000. Finally, Aristeia Capital L.L.C. acquired a new position in shares of TriSalus Life Sciences in the fourth quarter worth $43,000.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.